Published in

Elsevier, Parkinsonism & Related Disorders, 10(21), p. 1133-1144, 2015

DOI: 10.1016/j.parkreldis.2015.07.020

Links

Tools

Export citation

Search in Google Scholar

Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program

Journal article published in 2015 by Tobias Warnecke, Panagiotis Zikos, Richard Walsh, Pedro Jos e. Garcia Ruiz Espiga, Richard Walker, Paul Worth, P. Odin, Thomas Brücke, Walter Pirker, Gerhard Ransmayr, Petra Schwingenschuh, Volker Tomantschger, K. Ray Chaudhuri, Dieter Volc, Holger Jespersen and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are:. • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is 70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.